Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CRA-24781 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| CRA-24781 | DRUG | - |
Inclusion Criteria: * age ≥ 18 years * histologically confirmed solid or hematologic malignancy that is refractory to standard therapy or for which no standard therapy exists * estimated life expectancy \> 12 weeks * ECOG performance grade ≤ 2 * creatinine ≤ 1.5 X institutional upper limit of norma...
CRA-24781 is an investigational small molecule being studied for the treatment of hematologic neoplasms, which are cancers of the blood and bone marrow. It is in Phase 1 clinical development and has not been approved by regulatory authorities.
CRA-24781 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The drug is currently in Phase 1 clinical development for hematologic neoplasms.
CRA-24781 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 study of the drug has been completed, and it remains in early-stage clinical testing.
CRA-24781 has one completed clinical trial, NCT00473577, titled "Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients." This Phase 1 study enrolled 40 participants with hematologic neoplasms and other cancers in the United States.
Yes, CRA-24781 is also known as CRA-024781. The completed clinical trial NCT00473577 used the name CRA-024781 in its title, confirming that both names refer to the same investigational drug being developed by AbbVie.